Incyte (NASDAQ:INCY) Stock Gets Price Target Boost from Royal Bank Of Canada

Incyte (NASDAQ:INCY) had its price objective lifted by research analysts at Royal Bank Of Canada from $114.00 to $117.00 in a research note issued on Friday, Benzinga reports. The firm presently has a “sector perform” rating on the biopharmaceutical company’s stock. Royal Bank Of Canada‘s price target points to a potential downside of 3.29% from the stock’s current price.

INCY has been the subject of several other reports. Canaccord Genuity Group initiated coverage on shares of Incyte in a research report on Thursday, August 20th. They set a “buy” rating and a $152.00 price target for the company. Stifel Nicolaus lifted their price objective on Incyte from $145.00 to $157.00 and gave the company a “buy” rating in a research note on Monday, October 5th. Mizuho increased their price objective on Incyte from $121.00 to $137.00 and gave the company an “outperform” rating in a research report on Tuesday, August 4th. Leerink Partners boosted their price target on Incyte from $131.00 to $155.00 and gave the company an “outperform” rating in a research note on Monday, August 3rd. Finally, Oppenheimer set a $152.00 target price on shares of Incyte in a report on Tuesday. Twelve equities research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $132.95.

Incyte Stock Up 3.6%

Shares of NASDAQ:INCY traded up $4.18 during trading on Friday, reaching $120.98. 1,002,088 shares of the company traded hands, compared to its average volume of 1,729,539. Incyte has a 52 week low of $89.25 and a 52 week high of $132.60. The company’s 50 day moving average is $120.62 and its two-hundred day moving average is $108.07. The firm has a market capitalization of $24.52 billion, a PE ratio of 15.38, a PEG ratio of 4.83 and a beta of 0.74.

Incyte (NASDAQ:INCY) last released its quarterly earnings results on Thursday, October 29th. The biopharmaceutical company reported ($3.60) EPS for the quarter, beating analysts’ consensus estimates of ($3.93) by $0.33. Incyte had a return on equity of 29.93% and a net margin of 27.71%. The firm had revenue of $1.56 billion for the quarter, compared to analyst estimates of $1.46 billion. During the same quarter in the previous year, the company posted $2.26 EPS. The business’s revenue was up 14.0% on a year-over-year basis. As a group, research analysts anticipate that Incyte will post 1.97 EPS for the current year.

Insider Activity

In related news, insider Pablo Cagnoni sold 2,642 shares of the company’s stock in a transaction that occurred on Thursday, October 15th. The shares were sold at an average price of $112.71, for a total transaction of $297,779.82. Following the sale, the insider directly owned 183,200 shares of the company’s stock, valued at $20,648,472. This represents a 1.42% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 16.20% of the company’s stock.

Institutional Trading of Incyte

Several hedge funds have recently made changes to their positions in INCY. BlackRock Inc. purchased a new position in Incyte in the 2nd quarter valued at approximately $2,044,189,000. Legal & General Group Plc purchased a new position in Incyte during the second quarter worth $182,054,000. Caisse de depot et placement du Quebec purchased a new position in Incyte in the 2nd quarter valued at about $155,360,000. Deutsche Bank AG purchased a new position in shares of Incyte during the 2nd quarter worth $143,172,000. Finally, Bank of New York Mellon Corp acquired a new stake in shares of Incyte in the second quarter worth approximately $110,279,000. Institutional investors and hedge funds own 96.97% of the company’s stock.

Trending Headlines about Incyte

Here are the key news stories impacting Incyte this week:

• Positive Sentiment: Barclays raised its price target on Incyte from $139 to $143 and maintained an “overweight” rating, implying substantial upside from recent levels. Barclays analyst rating
• Positive Sentiment: Third-quarter revenue beat expectations. Incyte reported $1.56 billion in total revenue, up 14% year over year and above the $1.46 billion analyst consensus. Product demand was broad-based: Jakafi and Jakafi XR sales rose 4% to $827 million, Opzelura sales increased 36% to $255 million, and hematology and oncology portfolio sales climbed 38% to $235 million. Incyte Q3 results
• Positive Sentiment: Management increased its 2026 outlook. Full-year net-sales guidance was raised to $5.21 billion-$5.30 billion from $5.13 billion-$5.26 billion previously, while Opzelura guidance was lifted to $1.10 billion-$1.12 billion. The stronger outlook reinforces expectations for continued commercial momentum. Incyte raises 2026 guidance
• Neutral Sentiment: Analyst views remain mixed. One Seeking Alpha analysis upgraded Incyte to “hold,” arguing that recent ESMO-related developments had largely closed the valuation gap, while other analysts—including Barclays and Guggenheim—remain constructive. Incyte valuation analysis
• Negative Sentiment: Incyte posted a quarterly loss after recording a $1.23 billion in-process research and development charge tied to its Vega Therapeutics acquisition. The company reported a loss of $3.60 per share, although this was narrower than analysts expected and largely reflected the acquisition accounting charge. Incyte Q3 acquisition charge

About Incyte

Incyte Corporation is a biopharmaceutical company that discovers, develops and commercializes medicines for oncology and inflammatory or autoimmune diseases. The company focuses on therapies that target specific biological pathways, including Janus kinase (JAK), fibroblast growth factor receptor (FGFR) and other mechanisms involved in cancer and immune-related conditions.

Its key products include Jakafi (ruxolitinib), a JAK inhibitor used in the United States for certain blood cancers and graft-versus-host disease; Opzelura (ruxolitinib cream), a topical treatment for atopic dermatitis and nonsegmental vitiligo; and Pemazyre (pemigatinib), an FGFR inhibitor approved for selected patients with cholangiocarcinoma and certain myeloid or lymphoid neoplasms.